Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.31 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25829565 | 0.84 | KRAS (0.47) | — | |
| SCHEMBL25829610 | 0.82 | KRAS (0.36) | — | |
| SCHEMBL25829409 | 0.79 | KRAS (0.42) | — | |
| SCHEMBL25829488 | 0.78 | MAP4K1 (0.34) | GPR119SUV39H2NTRK1 | |
| SCHEMBL25829503 | 0.77 | KRAS (0.43) | — | |
| SCHEMBL25829616 | 0.74 | KRAS (0.42) | — | |
| SCHEMBL21099591 | 0.74 | GPR119 (0.37) | GPR119MEN1KMT2A | |
| SCHEMBL20807044 | 0.73 | KRAS (0.45) | — | |
| SCHEMBL25829573 | 0.73 | KRAS (0.51) | — | |
| SCHEMBL21099385 | 0.73 | GPR119 (0.36) | GPR119MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, WEE1 | GPR119 1070/4885SUV39H2 2754/4885NR1D1 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.